Drug Profile
Crisdesalazine - GNT Pharma
Alternative Names: AAD-2004Latest Information Update: 21 Feb 2023
Price :
$50
*
At a glance
- Originator Neurotech Pharmaceuticals
- Developer AmKor Pharma; GNT Pharma
- Class Anti-inflammatories; Antidementias; Antiparkinsonians; Salicylates; Small molecules; Sulfonamides
- Mechanism of Action Amyloid beta-protein inhibitors; Antioxidants; Dinoprostone antagonists; Free radical scavengers; Prostaglandin-E synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Alzheimer's disease; Amyotrophic lateral sclerosis; Depressive disorders; Parkinson's disease
- Preclinical Spinal muscular atrophy
- Discontinued Arthritis; Diabetes mellitus; Pain; Pancreatitis
Most Recent Events
- 21 Feb 2023 Discontinued - Preclinical for Pain in South Korea (unspecified route) (GNT Pharma pipeline; February 2023)
- 21 Feb 2023 Preclinical trials in Spinal muscular atrophy in South Korea (unspecified route) (GNT Pharma pipeline; February 2023)
- 20 Feb 2023 Phase-I development is ongoing for Alzheimer’s disease in South Korea (GNT Pharma pipeline; February 2023)